| SUBJECT： |
3rd Annual Antibody-Drug Conjugates |
| DATE： |
2013-05-02 |
| LOCATION： |
Boston (MA), USA, North America |
| CONTENT： |
Official Information:
Antibody-drug conjugates in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. This year’s third annual Antibody-Drug Conjugates, part of the PEGS Summit, will continue to highlight updates from the clinic, as well as progress in the development of the next generation of ADCs. Novel payloads, linkers and targets will be discussed, as well as lessons learned and best practices in conjugation chemistry, conjugation site selection, linker stability, and drug/antibody ratios. |
| Original file： |
No File
|
|
| Promulgator Detail |
| Contact: |
|
| Tel: |
|
| Fax: |
|
| E-mail: |
reply |
| Address: |
Boston (MA), USA, North America |
| Website: |
|
|
|
